Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions

Journal of the American Academy of Dermatology

Volumn 61, Issue 4, 2009, Pages 666-676

  Bremmer, Matthew S ^a   Bremmer, Samuel F ^a   Baig Lewis, Shahana ^a   Simpson, Eric L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

atopic dermatitis; biologics; immediate hypersensitivity reactions

Indexed keywords

ALEFACEPT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 2; MEPOLIZUMAB; OMALIZUMAB; PLACEBO; RECOMBINANT GAMMA INTERFERON; RITUXIMAB; TOPICAL AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ALOPECIA AREATA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; CHILL; CLINICAL TRIAL; CONTACT ALLERGY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; FEVER; FLU LIKE SYNDROME; FLUSHING; FOOD ALLERGY; GRANULOCYTOPENIA; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; LEG PAIN; LICHENOID ERUPTION; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REBOUND; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; SYSTEMIC THERAPY; TH1 CELL; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRAL GASTROENTERITIS;

BIOLOGICAL THERAPY; DERMATITIS, ATOPIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; RISK FACTORS;

EID: 69949179194     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.02.041     Document Type: Review

References (67)

1. Simpson E.L., and Hanifin J.M. Periodic synopsis on atopic dermatitis. J Am Acad Dermatol 53 (2005) 115-128
2. Schmitt J., Schäkel K., Schmitt N., and Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 87 (2007) 100-111
3. Austen K.F. Systemic anaphylaxis in the human being. N Engl J Med 291 (1974) 661-664
4. Heine R.G., Laske N., and Hill D.J. The diagnosis and management of egg allergy. Curr Allergy Asthma Rep 6 (2006) 145-152
5. Eigenmann P.A., Sicherer S.H., Borkowski T.A., Cohen B.A., and Sampson H.A. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101 (1998) E8
6. Langley S.J., Goldthorpe S., Craven M., Woodcock A., and Custovic A. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitized, atopic asthmatic subjects. Thorax 60 (2005) 17-21
7. Rennick G.J., Moore E., and Orchard D.C. Skin prick testing to food allergens in breast-fed young infants with moderate to severe atopic dermatitis. Australas J Dermatol 47 (2006) 41-45
8. Hill D.J., and Hosking C.S. Food allergy and atopic dermatitis in infancy: an epidemiologic study. Pediatr Allergy Immunol 15 (2004) 421-427
9. Miraglia del Giudice M., Decimo F., Leonardi S., Maioello N., Amelio R., Capasso A., et al. Immune dysregulation in atopic dermatitis. Allergy Asthma Proc 27 (2006) 451-455
10. Laske N., Bunikowski R., and Niggemann B. Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann Allergy Asthma Immunol 91 (2003) 202-204
11. Hill D.J., Sporik R., Thorburn J., and Hosking C.S. The association of atopic dermatitis in infancy with immunoglobulin E food sensitization. J Pediatr 137 (2000) 475-479
12. Boger W.P., Sherman W.B., Schiller I.W., Siegal S., and Rose B. Allergic reactions to penicillin: a panel discussion. J Allergy 24 (1953) 383-404
13. Rajka G., and Skog E. On the relation between drug allergy and atopy. Acta Allergol 20 (1965) 387-394
14. Parker C.W. Medical intelligence. Drug therapy: drug allergy (first of three parts). N Engl J Med 292 (1975) 511-514
15. Stember R.H., and Levine B.B. Prevalence of allergic diseases, penicillin hypersensitivity, and aeroallergen hypersensitivity in various populations. J Allergy Clin Immunol 51 (1973) 100
16. Green G.R., and Rosenblum A. Report of the penicillin study group-American Academy of Allergy. J Allergy Clin Immunol 48 (1971) 331-343
17. Horowitz L. Atopy as factor in penicillin reactions. [letter]. N Engl J Med 292 (1975) 1243-1244
18. Leung D.Y. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 96 (1995) 302-318
19. Kimura M., Tsuruta S., and Yoshida T. Unique profile of IL-4 and IFN-gamma production by peripheral blood mononuclear cells in infants with atopic dermatitis. J Allergy Clin Immunol 102 (1998) 238-244
20. Ackermann L., and Harvima I.T. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 290 (1998) 353-359
21. + T cells initiate atopic dermatitis lesions. J Immunol 178 (2007) 5571-5577
22. Itazawa T., Adachi Y., Okabe Y., Hamamichi M., Adachi Y.S., Toyoda M., et al. Developmental changes in interleukin-12-producing ability by monocytes and their relevance to allergic diseases. Clin Exp Allergy 33 (2003) 525-530
23. Jacobi A., Antoni C., Manger B., Schuler G., and Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52 (2005) 522-526
24. Cassano N., Loconsole F., Coviello C., and Vena G.A. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 19 (2006) 237-240
25. Buka R.L., Resh B., Roberts B., Cunningham B.B., and Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53 (2005) 358-359
26. Wright R.C. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 49 (2003) 160-161
27. Mangge H., Gindl S., Kenzian H., and Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 30 (2003) 2506-2507
28. Chan J.L., Davis-Reed L., and Kimball A.B. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 3 (2004) 315-318
29. Omalizumab [package insert]. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed March 28, 2009.
30. Leung D.Y., Schneeberger E.E., Siraganian R.P., Geha R.S., and Bhan A.K. The presence of IgE on macrophages and dendritic cells infiltrating into the skin lesion of atopic dermatitis. Clin Immunol Immunopathol 42 (1987) 328-337
31. Mudde G.C., Van Reijsen F.C., Boland G.J., de Gast G.C., Bruijnzeel P.L., and Bruijnzeel-Koomen C. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology 69 (1990) 335-341
32. Herrick C.A., MacLeod H., Glusac E., Tigelaar R.E., and Bottomly K. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 105 (2000) 765-775
33. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., and Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101 (1998) 1614-1622
34. Flohr C., Johansson S.G.O., Wahlgren C.-F., and Williams H. How atopic is atopic dermatitis?. J Allergy Clin Immunol 114 (2004) 150-158
35. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., and Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55 (2006) 168-170
36. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., and Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006) 68-72
37. Forman S.B., and Garrett A.B. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis 80 (2007) 38-40
38. Krathen R.A., and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 (2005) 338-340
39. Beck L.A., and Saini S. Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55 (2006) 540-541
40. Cox L., Platts-Mills T.A.E., Finegold I., Schwartz L.B., Simons E.R., and Wallace D.V. American College of Allergy, Asthma and Immunology task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120 (2007) 1373-1377
41. Takiguchi R., Tofte S., Simpson B., Harper E., Blauvelt A., Hanifin J., et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 56 (2007) 222-227
42. Hassan A.S., Kaelin U., Braathen L.R., and Yawalkar N. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 56 (2007) 217-221
43. Farshidi A., and Sadeghi P. Successful treatment of severe refractory atopic dermatitis with efalizumab. J Drugs Dermatol 5 (2006) 994-998
44. Weinberg J.M., and Siegfried E.C. Successful treatment of severe atopic dermatitis in a child and an adult with the T cell modulator efalizumab. Arch Dermatol 142 (2006) 555-558
45. Efalizumab [package insert]. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed March 28, 2009.
46. Siegfried E.C. Long-term follow-up of a child treated with efalizumab for atopic dermatitis. Arch Dermatol 143 (2007) 1077-1078
47. Wassom D.L., Loegering D.A., Solley G.O., Moore S.B., Schooley R.T., Fauci A.S., et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 67 (1981) 651-661
48. Silberstein D.S., Austen K.F., and Owen Jr. W.F. Hemopoietins for eosinophils: glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease. Hematol Oncol Clin North Am 3 (1989) 511-533
49. Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 as an eosinophil chemotactic factor. J Exp Med 167 (1988) 1737-1742
50. Phipps S., Flood-Page P., Menzies-Gow A., Ong Y.E., and Kay A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122 (2004) 1406-1412
51. Oldhoff J.M., Darsow U., Werfel T., Katzer K., Wulf A., Laifaoui J., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60 (2005) 693-696
52. Jujo K., Renz H., Abe J., Gelfand E.W., and Leung D.Y. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol 90 (1992) 323-331
53. Coffman R.L., and Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 136 (1986) 949-954
54. Hanifin J.M., Schneider L.C., Leung D.Y., Ellis C.N., Jaffe H.S., Izu A.E., et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28 (1993) 189-197
55. Stevens S.R., Hanifin J.M., Hamilton T., Tofte S.J., and Cooper K.D. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 134 (1998) 799-804
56. Reinhold U., Wehrmann W., Kukel S., and Kreysel H.-W. Recombinant interferon-γ in severe atopic dermatitis. Lancet 335 (1990) 1282
57. Reinhold U., Kukel S., Brzoska J., and Kreysel H.-W. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 29 (1993) 58-63
58. Horneff G., Dirksen U., and Wahn V. Interferon-γ for treatment of severe atopic eczema in two children. Clin Investig 72 (1994) 400-403
59. Boguniewicz M., Jaffe H.S., Izu A., Sullivan M.J., York D., Geha R.S., et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 88 (1990) 365-370
60. Schneider L.C., Baz Z., Zarcone C., and Zurakowski D. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 80 (1998) 263-268
61. Jang I.G., Yang J.K., Lee H.J., Yi J.Y., Kim H.O., Kim C.W., et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42 (2000) 1033-1040
62. Noh G.W., and Lee K.Y. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 53 (1998) 1202-1207
63. Rituximab [package insert]. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed March 28, 2009.
64. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 48 (2003) 1484-1492
65. Simon D., Hösli S., Kostylina G., Yawalkar N., and Simon H.U. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121 (2008) 122-128
66. Mehlis S.L., and Gordon K.B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 49 Suppl (2003) S44-S50
67. Moul D.K., Routhouska S.B., Robinson M.R., and Korman N.J. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 58 (2008) 984-989